The CEACAM1 expression is decreased in the liver of severely obese patients with or without diabetes

Wonae Lee

Abstract
Background: Type 2 diabetes is mainly caused by insulin resistance. The carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) is an important candidate for causing insulin resistance.

Methods: The CEACAM1 expression was evaluated immunohistochemically in the liver tissues of 99 severely obese or non-obese subjects with or without diabetes. The CEACAM1 expression was classified into two categories: a normal expression or a decreased expression.

Results: The CEACAM1 expression was markedly decreased in the hepatocytes with macrovesicular steatosis. A decreased CEACAM1 expression was noted in 29 (29%) of 99 cases. The incidence of a decreased CEACAM1 expression was significantly higher in high grade fatty liver as well as severe obesity with or without diabetes (p < 0.05). The incidence of a decreased CEACAM1 expression was not different between the diabetic and non-diabetic groups.

Conclusions: This data supports that a decreased CEACAM1 expression is related to obesity and a fatty liver.

Background
Diabetes is one of the most problematic diseases in the world, and it is a group of metabolic disease sharing hyperglycemia. Approximately 90-95% of diabetic patients have type 2 diabetes in which insulin resistance predates the development of hyperglycemia and then β-cell dysfunction ensues [1,2]. The molecular cause of insulin resistance is very complicated and this has not yet been clarified. The recent data from articles suggests that carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) is an important candidate molecules that may cause insulin resistance.

CEACAM1 protein is also known as CD66a protein, and the CEACAM1 gene is a human gene that encodes a member of the carcinoembryonic antigen gene family [3,4]. CEACAM1 protein has been implicated in intra-cellular adhesion, intracellular signaling that governs the growth and differentiation of normal and cancerous cells, and the modulation of immune responses [3,5-8].

CEACAM1 protein is a cell-cell adhesion molecule detected in the pericannalicular region of hepatocytes [9]. CEACAM1 is a liver-specific transmembrane glycoprotein and it is also a substrate of insulin receptor in liver [10,11]. CEACAM1 is phosphorylated in response to insulin in hepatocytes and it plays a role in insulin clearance by increasing receptor-mediated endocytosis [12,13]. Inactivation of CEACAM1 impairs insulin clearance and causes hyperinsulinemia, insulin resistance, dyslipidemia and visceral adiposity in transgenic mice [14]. Thus, there is a strong association between severe visceral obesity, insulin resistance and a reduced hepatic CEACAM1 level [14,15].

The studies that have focused on CEACAM1 related to insulin resistance have mainly been done on experimental animal models and using molecular biologic methods [14,15]. Immunohistochemical studies for determining the CEACAM1 expression have rarely been done in human non-neoplastic liver tissue. The aim of this study is to evaluate the expression of CEACAM1 in the human liver tissue of diabetics and non-diabetics who are with or without severe obesity.
Methods

Subjects and samples
A total of 99 cases of liver tissue obtained from diabetic or non-diabetic subjects with or without severe obesity were selected for this study. The age of subjects ranged from 32 to 81 years old (mean: 58.0). Forty cases were obtained from severely obese patients whose body mass index (BMI) ranged from 34 to 67 (mean: 49). They underwent bariatric surgery at the Wakefield hospital in New Zealand. Liver wedge biopsies were done during the gastric bypass surgeries. The average biopsy size was about 2 mm at the greatest dimension. Twenty of 40 severely obese patients had diabetes and 20 of them were non-diabetics. Eight of the 20 severely obese non-diabetics had an abnormal oral glucose tolerance test and they had not yet developed diabetes. Fifty-nine cases were not severely obese patients who were selected from the files of Dankook University Hospital. These patients underwent hepatectomy due to primary or metastatic liver tumor or hepatolithiasis. Among the 59 non-obese patients, 29 patients had diabetes and 30 patients were non-diabetics. Using the paraffin blocks of the hepatectomy specimens, a tissue microarray with 2 mm-sized cores was made. Histologically, all cases were examined for the degree of fatty liver which was graded as low grade = fatty change in more than 5% and less than 33% of hepatocytes and high grade = fatty change in more than 33% of hepatocytes. The severely obese cases were examined for nonalcoholic steatohepatitis (NASH) according to standarized criteria recommended [16]. The liver of non-obese group was not examined for NASH because this group was heterogeneous and inadequate to be assessed for NASH.

Immunohistochemistry
Immunohistochemical staining was done using the formalin-fixed paraffin-embedded sections. The sections were deparaffinized with xylene and rehydrated with ethanol. Microwave antigen retrieval was performed with 10 mM sodium citrate buffer. The sections were incubated for 20 minutes in 0.3% H₂O₂ to block the endogenous peroxidase activity. The sections were then incubated with primary antibody for 60 minutes at room temperature. The primary antibody used was anti-CEACAM-1 mouse monoclonal antibody (1:50, 29H2, Abcam, Cambridge, UK). After washing, the sections were incubated with ImmPRESS™ universal reagent (Abcam) for 40 minutes. Next the sections were incubated with 3, 3'-diaminobenzidine substrate (Zymed, South San Francisco, CA) for 5 min, washed, counterstained with Mayer’s hematoxylin, rinsed and mounted.

The CEACAM1 expression was classified into two categories according to the previous report: a normal expression when positive membranous staining was noted throughout the examined liver specimen or a decreased expression when distinct areas of negative staining were noted within the examined liver specimen [16].

Statistical analysis
Statistical analysis was performed by using the chi-square test. The results were considered to be statistically significant when the p values were less than 0.05. All statistical analyses were conducted using the SPSS 12.0 statistical software program (SPSS, Chicago, IL, USA).

Results
The relationship of fatty liver and high grade fatty liver with diabetics and severe obesity was summarized in Table 1. Some degree of fatty liver was noted in 63 (64%) of the total of 99 subjects: in 37 (93%) of 40 severely obese subjects and in 26 (44%) of 59 non-obese subjects. The incidence of fatty liver was significantly higher in the severely obese group than the non-obese group (p < 0.05). High grade fatty liver was noted in 35 (35%) of the 99 subjects: in 34 (85%) of 40 severely obese subjects and in 1 (2%) of 59 non-obese subjects. The incidence of high grade fatty liver was also significantly higher in the severely obese group than the non-obese group (p < 0.05). The incidence of fatty liver and high grade fatty liver was not different between the diabetics and non-diabetes groups. Twenty four cases (57.5%) of 40 severely obese patients were considered as NASH. All NASH cases were associated with high grade fatty liver.

Table 1 Relationship of fatty liver and high grade fatty liver with diabetes and severe obesity

|                     | Total (n = 99) | Fatty liver (n = 63) | High grade fatty liver (n = 35) |
|---------------------|---------------|---------------------|-------------------------------|
|                     | No (%)        | p-value             | No (%)                        | p-value             |
| Diabetics           |               |                     |                               |                     |
| No                  | 50            | 30 (60)             | 16 (32)                       | 0.447               |
| Yes                 | 49            | 33 (67)             | 19 (39)                       | 0.481               |
| Severe obesity      |               |                     |                               |                     |
| No                  | 59            | 26 (44)             | <0.0009                       | 1 (2)               |
| Yes                 | 40            | 37 (93)             | 34 (85)                       | <0.0009             |
CEACAM1 protein was strongly expressed alongside the canalicular membrane of hepatocytes (Figure 1). The CEACAM1 expression was lost mainly in the hepatocytes with fatty change, particularly macrovesicular steatosis (Figure 2). The relationship of a CEACAM1 expression with diabetes, severe obesity, high grade fatty liver and NASH was summarized in Table 2. A decreased CEACAM1 expression was noted in 29 (29%) of 99 cases. A decreased CEACAM1 expression was associated with high grade fatty change compared to absent or low grade fatty change (p < 0.05). A decreased CEACAM1 expression was also associated with severe obesity with or without diabetes rather than being associated with non-obesity with or without diabetes (p < 0.05). The incidence of a decreased CEACAM1 expression was significantly higher in severely obese patients with NASH than severely obese patients without NASH (p < 0.05). The incidence of CEACAM1 expression was not different between the diabetic and non-diabetic groups. A decreased CEACAM1 expression was noted in following descending order, severely obese diabetics, severely obese non-diabetics, non-obese diabetics and non-obese non-diabetics (p < 0.05) (Table 3). The relationship of high grade fatty liver, NASH and CEACAM1 expression with severely obese patients that were grouped into diabetics, non-diabetics with abnormal glucose test and non-diabetics with normal glucose test, was summarized in Table 4. There were no statistically significant differences in high grade fatty liver, NASH and a decreased CEACAM1 expression between 3 groups of severely obese patients.

Discussion

Type 2 diabetes is caused by a combination of impaired insulin secretion and insulin resistance, but their relative contribution to the development of hyperglycemia may differ due to the heterogeneity of this disease [2]. In response to physiologic stimuli, insulin is secreted from the pancreatic β-cells into the portal circulation in a pulsatile manner [17]. Through its first passage, approximately 50% of the secreted insulin is cleared in the liver [18,19]. Insulin clearance in liver is a critical regulator of insulin’s action [19,20]. Impaired insulin clearance can be the primary cause of insulin resistance by causing down-regulation of insulin receptors and hepatic lipogenesis [14,19]. CEACAM1 plays an important role in insulin clearance by receptor-mediated insulin endocytosis and degradation in the liver [12,18]. Abnormalities of insulin clearance are present in various pathological conditions including type 2 diabetes and severe obesity [19].

Obesity is intimately associated with the development of insulin resistance and type 2 diabetes [21-23]. In obese individuals, the adipose tissue releases increased amounts of non-esterified fatty acids, glycerol, hormones, pro-inflammatory cytokines and other factors that are involved in the development of insulin resistance [24-28]. When insulin resistance is accompanied by dysfunction of pancreatic islet beta-cells, this results in the development of diabetes [1,25]. The homeostasis model assessment for insulin resistance (HOMA-R) is strongly related to the waist circumference and BMI [29]. In the present study, 40% of the severely obese non-diabetic group had abnormal oral glucose tolerance testing, and this reflect the presence of insulin resistance, and the remainder of the severely obese group might also be associated with some degree of insulin resistance because they had extremely high BMI. So, the higher incidence of a decreased CEACAM1 expression in severely obese non-diabetic group than non-obese non-diabetic group reflects the possible association between a decreased hepatic CEACAM expression and insulin resistance.
Figure 2 The liver tissue is associated with severe fatty change (A) and it shows a distinct loss of CEACAM1 expression immunohistochemically (B).

Table 2 Relationship of a decreased CEACAM1 expression with diabetes, severe obesity, high grade fatty liver and non-alcoholic steatohepatitis

|                      | Total (n = 99) | Decreased CEACAM1 expression (n = 29) (%) | p-value |
|----------------------|---------------|------------------------------------------|---------|
|                      |               |                                          |         |
| Diabetics            |               |                                          |         |
| No                   | 50            | 13 (26)                                  | 0.467   |
| Yes                  | 49            | 16 (33)                                  |         |
| Severe obesity       |               |                                          |         |
| No                   | 59            | 1 (2)                                    | <0.0009 |
| Yes                  | 40            | 28 (70)                                  |         |
| High grade fatty liver |             |                                          |         |
| No                   | 64            | 0 (0)                                    | <0.0009 |
| Yes                  | 35            | 29 (83)                                  |         |
| Non-alcoholic steatohepatitis* |     |                                          | <0.0009 |
| No                   | 17            | 6 (35)                                   |         |
| Yes                  | 23            | 22 (96)                                  |         |

* Only 40 severely obese patients was examined for non-alcoholic steatohepatitis

Table 3 Relationship of high grade fatty liver and a decreased CEACAM1 expression with diabetics and non-diabetics with or without severe obesity

|                      | Total (n = 99) | High grade fatty liver (n = 35) | Decreased CEACAM1 expression (n = 29) | p-value | p-value |
|----------------------|---------------|--------------------------------|---------------------------------------|---------|---------|
|                      |               |                                |                                       |         |         |
| Severely obese diabetics | 20           | 18 (90)                        | 15 (75)                               | <0.0009 | <0.0009 |
| Severely obese non-diabetics | 20          | 16 (80)                        | 13 (65)                               |         |         |
| Non-obese diabetics    | 29            | 1 (3)                          | 1 (3)                                 |         |         |
| Non-obese non-diabetics | 30           | 0 (0)                          | 0 (0)                                 |         |         |

Table 4 High grade fatty liver, non-alcoholic steatohepatitis and a decreased CEACAM1 expression between 3 groups of severely obese patients

|                      | Total (n = 40) | High grade fatty liver (n = 34) | Non-alcoholic steatohepatitis (n = 23) | Decreased CEACAM1 expression (n = 28) | p-value | p-value | p-value |
|----------------------|---------------|--------------------------------|---------------------------------------|---------------------------------------|---------|---------|---------|
|                      |               |                                |                                       |                                       |         |         |         |
| Diabetics            | 20            | 18 (90)                        | 13 (65)                               | 15 (75)                               | 0.574   |         |         |
| Non-diabetics         | 8             | 8 (100)                        | 5 (65)                                | 6 (75)                                |         |         |         |
| with abnormal GTT    |               |                                |                                       |                                       |         |         |         |
| Non-diabetics with normal GTT | 12        | 8 (67)                         | 5 (41)                                | 7 (58)                                |         |         |         |

GTT: glucose tolerance test
In the present study, the CEACAM1 expression was not different between the diabetics and non-diabetics in the obese or non-obese groups. This result does not support the previous experimental animal model studies [11,12]. It could have been caused by the limitation of immunohistochemical study for conducting a quantitative analysis. In obese group, the CEACAM1 expression was not different between the diabetics and non-diabetics with normal or abnormal glucose tolerance test, yet both the obese diabetic and obese non-diabetic groups had significantly decreased CEACAM1 expression rather than non-obese group. This data suggest the following hypothesis: because a decreased CEACAM1 expression in the obese group is an early event that occurs at the time of insulin resistance and it consistently persists with overt diabetes on a same level, the difference of the CEACAM1 expression between the obese diabetic and obese non-diabetic groups cannot be observed. To clarify this, further study using more a precise analytic method such as Western or Northern blotting is necessary.

Najjar et al [12,30] reported that transgenic mice, phosphorylation-defective S503A-CEACAM1 mutant developed visceral obesity with an increased amount of plasma free fatty acid and plasma and hepatic triglyceride content. Subsequently, they reported that CEACAM1 null mice showed the loss of insulin’s ability to acutely decrease the hepatic fatty acid synthase (FAS) activity [30]. Generally, insulin is viewed as a positive regulator of fatty acid synthesis by increasing the transcription of FAS mRNA [30]. However, insulin acutely reduces the hepatic FAS activity by inducing phosphorylation of CEACAM1 and its interaction with FAS [30]. This mechanism acts to reduce the hepatic lipogenesis incurred by insulin pulses during refeeding [30]. In the present study, the CEACAM1 expression in the liver was significantly decreased in the severely obese subjects, high grade fatty livers and NASH. Interestingly, the hepatocytes with fatty change, and particularly those with macrovesicular steatosis, revealed the loss of a CEACAM1 expression. This data is in agreement with Najjar et al [11,12,14]’s data from experimental animal models.

Liver steatosis is frequently found in type 2 diabetics and in severely obese patients [21,23,31]. One study reported that steatosis was found in 86% of the severely obese subjects who undergo bariatric surgery [32]. In the severely obese group of the present study, 93% of these subjects had an associated fatty liver. Moreover, the degree of fatty liver was mainly high grade. The incidence and grade of fatty liver were not different between the diabetic and non-diabetic groups among the obese groups. This data suggests the hypothesis that a fatty liver is more likely related to the degree of obesity rather than to the blood glucose level in the pathogenesis of fatty liver associated with obese people with or without diabetes.

In conclusion, the CEACAM1 expression was decreased in the liver of severely obese patients with or without diabetes. This study supports that a decreased CEACAM1 expression in liver is related to obesity and a fatty liver. However, the relation between decreased CEACAM1 expression and diabetes was not supported in this study. Larger series with more complex studies are needed to further clarify this.

Acknowledgements
The author thanks Richard Stubbs and Mark Hayes for providing samples and discussing research ideas and Jane Anderson and Jai Wan Lee for their technical assistance. This research was supported by the Korea Research Foundation Grant (KRF-2008-013-E00006).

Authors’ contributions
WAL designed the study, performed literature review, examined immunohistochemistry and prepared the manuscript.

Competing interests
The author declares that they have no competing interests.

Received: 21 December 2010 Accepted: 11 May 2011
Published: 11 May 2011

References
1. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006, 444(7121):840-846.
2. Groop L. Pathogenesis of type 2 diabetes: the relative contribution of insulin resistance and impaired insulin secretion. Int J Clin Pract Suppl 2000, 113: 3-13.
3. Obrink B: CEA adhesion molecules: multifunctional proteins with signal-regulatory properties. Curr Opin Cell Biol 1997, 9(5):616-626.
4. Barnett TR, Kretschmer A, Austen DA, Goebel SJ, Hart JT, Elting JJ, Kamack ME: Carcinoembryonic antigens: alternative splicing accounts for the multiple mRNAs that code for novel members of the carcinoembryonic antigen family. J Cell Biol 1989, 108(2):267-276.
5. Cruz PV, Wakai T, Shirai Y, Yokoyama N, Hatakeyama K: Loss of carcinoembryonic antigen-related cell adhesion molecule 1 expression is an adverse prognostic factor in hepatocellular carcinoma. Cancer 2005, 104(2):354-360.
6. Nollau P, Prall F, Helmchen U, Wagener C, Neumaier M: Dysregulation of carcinoembryonic antigen group members CGM2, CD66a (biliary glycoprotein), and nonspecific cross-reacting antigen in colorectal carcinomas. Comparative analysis by northern blot and in situ hybridization. Am J Pathol 1997, 151(2):521-530.
7. Gray-Dweyn SD, Blumberg RS: CEACAM1: contact-dependent control of immunity. Nat Rev Immunol 2006, 6(6):433-446.
8. Fournes B, Sadekova S, Turbide C, Letoumeau S, Beauchemin N: The CEACAM1-L Ser503 residue is crucial for inhibition of colon cancer cell tumorigenicity. Oncogene 2001, 20(2):219-230.
9. Mowery J, Hixson DC: Detection of cell-CAM 105 in the pericanalicular domain of the rat hepatocyte plasma membrane. Hepatology 1991, 13(1):47-56.
10. Poy MN, Yang Y, Rezaei K, Fernstrom K, Lee AD, Kido Y, Erickson SK, Najjar SM: CEACAM1 regulates insulin clearance in liver. Nat Genet 2002, 32(3):270-276.
11. Najjar SM, Philippe N, Suzuki Y, Ignacio GA, Formisano P, Accili D, Taylor SI: Insulin-stimulated phosphorylation of recombinant pp120/HA4, an endogenous substrate of the insulin receptor tyrosine kinase. Biochemistry 1995, 34(29):9341-9349.
12. Najjar SM: Regulation of insulin action by CEACAM1. Trends Endocrinol Metab 2002, 13(6):240-245.
13. Soni P, Al-Hosaini KA, Fernstrom MA, Najjar SM: Cell adhesion properties and effects on receptor-mediated insulin endocytosis are independent properties of pp120, a substrate of the insulin receptor tyrosine kinase. Mol Cell Biol Res Commun 1999, 1(2):102-108.

14. DeAngelis AM, Heinrich G, Dai T, Bowman TA, Patel PR, Lee SJ, Hong EG, Jung DY, Assmann A, Kulkarni RH, et al: Carcinoembryonic antigen-related cell adhesion molecule 1: a link between insulin and lipid metabolism. Diabetes 2008, 57(9):2296-2303.

15. Dai T, Abou-Rjaily GA, Al-Share QY, Yang Y, Fernstrom MA, Deangelis AM, Lee AD, Sweetman L, Amato A, Pasquali M, et al: Interaction between altered insulin and lipid metabolism in CEACAM1-inactive transgenic mice. J Biol Chem 2004, 279(43):45155-45161.

16. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Uralp-Arida A, et al: Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41(6):1313-1321.

17. Bergman RN: Non-esterified fatty acids and the liver: why is insulin secreted into the portal vein? Diabetologia 2000, 43(7):946-952.

18. Duckworth WC: Insulin degradation: mechanisms, products, and significance. Endocr Rev 1988, 9(3):319-345.

19. Duckworth WC, Bennett RG, Hamel FG: Insulin degradation: progress and potential. Endocr Rev 1998, 19(5):608-624.

20. Duckworth WC, Hamel FG, Peavy DE: Hepatic metabolism of insulin. Am J Med 1988, 85(SA):71-76.

21. Scheen AJ, Luyckx FH: Obesity and liver disease. Best Pract Res Clin Endocrinol Metab 2002, 16(4):703-716.

22. Arner P: The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrinol Metab 2003, 14(3):137-145.

23. Cusi K: The role of adipose tissue and lipotoxicity in the pathogenesis of type 2 diabetes. Curr Diab Rep 2004, 4(3):306-315.

24. Samuel VT, Petersen KE, Shulman GI: Lipid-induced insulin resistance: unravelling the mechanism. Lancet 375(9733):2267-2277.

25. Kahn SE, Zinman B, Haffner SM, O’Neill MC, Kivitz BG, Yu D, Freed MI, Herman WH, Holman RR, Jones NP, et al: Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes. Diabetes 2006, 55(8):2357-2364.

26. DeFronzo RA: Dysfunctional fat cells, lipotoxicity and type 2 diabetes. Int J Clin Pract Suppl 2004, 143:9-21.

27. Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, Capeau J, Feve B: Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006, 17(1):4-12.

28. Sell H, Eckel J: Chemotactic cytokines, obesity and type 2 diabetes: in vivo and in vitro evidence for a possible causal correlation? Proc Nutr Soc 2009, 68(4):378-384.

29. Kawada T: Insulin resistance, as expressed by HOMA-R, is strongly determined by waist circumference or body mass index among Japanese working men. Intern Med 2004, 43(9):1044-1046.

30. Najjar SM, Yang Y, Fernstrom MA, Lee SJ, Deangelis AM, Rjaily GA, Al-Share QY, Dai T, Miller TA, Ratnam S, et al: Insulin acutely decreases hepatic fatty acid synthase activity. Cell Metab 2005, 2(1):43-53.

31. Van Steenbergen W, Lanckmans S: Liver disturbances in obesity and diabetes mellitus. Int J Obes Relat Metab Disord 1995, 19(Suppl 3):S27-36.

32. Marceau P, Boucher V, Hould FS, Marceau S, Simard S, Thung SN, Koal JK: Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999, 84(5):1513-1517.

doi:10.1186/1746-1596-6-40
Cite this article as: Lee: The CEACAM1 expression is decreased in the liver of severely obese patients with or without diabetes. Diagnostic Pathology 2011 6:40.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit